SOPHiA GENETICS Q3 Earnings Call Highlights
SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.
How this was made
The 30-second read
Why it matters
Key decision inputs are the reaffirmed 2026 revenue and adjusted EBITDA loss ranges, the stated cash balance, and the management expectation for positive adjusted EBITDA in 2H 2027.
Market read
Traders can update expectations for the company’s path to profitability using the reaffirmed guidance and quarter metrics (retention, churn, adjusted EBITDA improvement).
What to watch
The article flags potential FX-driven revenue headwinds in Q4 if rates persist, which could offset operational improvements and affect near-term reported growth.
Background
The piece summarizes SOPHiA GENETICS Q3 earnings call highlights, focusing on customer growth, retention, liquid biopsy adoption, biopharma collaborations, and updated guidance.
Ticker impact
SOPHiA GENETICS reaffirmed 2026 revenue guidance and adjusted EBITDA loss range, while highlighting net dollar retention at 118% and cash of $94M.
Likely modest upward bias as investors weigh improving operating efficiency against the still-negative adjusted EBITDA trajectory.
The article provides fresh quarter metrics (retention, churn, adjusted EBITDA loss improvement) and reaffirmed 2026 targets, which typically move sentiment even without a surprise beat or raise.
Market effects
Reinforces demand momentum for AI-enabled genomic data platforms and liquid biopsy adoption, potentially supportive for healthcare genomics sentiment.
Emphasizes scaling liquid biopsy adoption efforts across Europe, Asia, and Latin America, which may influence regional payer and provider expectations.
Biopharma collaboration expansion signals continued global use of real-world evidence and companion diagnostic workflows in oncology trials.
Counterpoint
Despite retention strength, the company still guides to a sizable adjusted EBITDA loss for 2026, so valuation may remain sensitive to execution risk and FX headwinds.
Key entities
- companySOPHiA GENETICS
NASDAQ-listed healthcare technology company providing AI-driven genomic medicine analytics and liquid biopsy applications.
- companyAstraZeneca
Biopharma partner referenced for two companion diagnostic programs in prostate cancer and hematological oncology.
